HERO TEXT

Ulacamten (CK-586)

Cardiac myosin inhibitor

Ulacamten (CK-586) is designed to be a novel, selective, oral, small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction (HFpEF). Ulacamten was designed to selectively inhibit the ATPase of intact cardiac myosin but does not inhibit the ATPase of subfragment-1 of myosin (S1).

In preclinical models, ulacamten reduced cardiac hypercontractility by decreasing the number of active myosin cross-bridges during cardiac contraction thereby reducing the contractile force, without effect on calcium transients.

Ulacamten was evaluated in a Phase 1 study assessing the safety, tolerability and pharmacokinetics of single and multiple oral doses of Ulacamten. Ulacamten is now the subject of AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF), a Phase 2 clinical trial in a subgroup of patients with symptomatic HFpEF with hypercontractility and ventricular hypertrophy.

Ulacamten is an investigational product and is not approved by any regulatory agency. Its safety and effectiveness have not been established.